Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections

Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections

(2013) T. Wang et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology

(2013) H. R. Ashbee et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial

(2012) Wan Beom Park et al.   CLINICAL INFECTIOUS DISEASES

Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokinetics–Based Analysis of Adult Patients With Invasive Fungal Infections

(2012) Andres Pascual et al.   CLINICAL INFECTIOUS DISEASES

Steady-State Plasma Pharmacokinetics of Oral Voriconazole in Obese Adults

(2011) Manjunath P. Pai et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients

(2011) Peter F. Troke et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Fusarium verticillioides fungemia in a liver transplantation patient: successful treatment with voriconazole

(2011) Stefania Cocchi et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Voriconazole Pharmacokinetics in Liver Transplant Recipients

(2009) H. J. Johnson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes

(2009) Kazuaki Matsumoto et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders

(2009) Koki Ueda et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Antifungal drugs: predicting clinical efficacy with pharmacodynamics

(2009) Michael D Nailor et al.   Expert Review of Clinical Pharmacology

Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria

(2008) Brahm H. Segal et al.   CLINICAL INFECTIOUS DISEASES

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

(2008) Ben De Pauw et al.   CLINICAL INFECTIOUS DISEASES

CYP2C19Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole

(2008) Johanna Weiss et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Antifungal agents – clinical pharmacokinetics and drug interactions

(2008) Hans-Peter Lipp   MYCOSES

Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes

(2007) A. Pascual et al.   CLINICAL INFECTIOUS DISEASES